BridgeBio Pharma Retained Earnings (Accumulated Deficit) 2018-2024 | BBIO

BridgeBio Pharma retained earnings (accumulated deficit) from 2018 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
BridgeBio Pharma Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $-2,561
2022 $-1,918
2021 $-1,437
2020 $-889
2019 $-440
2018 $-179
2017 $
BridgeBio Pharma Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $-2,831
2024-06-30 $-2,669
2024-03-31 $-2,596
2023-12-31 $-2,561
2023-09-30 $-2,392
2023-06-30 $-2,215
2023-03-31 $-2,057
2022-12-31 $-1,918
2022-09-30 $-1,781
2022-06-30 $-1,643
2022-03-31 $-1,633
2021-12-31 $-1,437
2021-09-30 $-1,290
2021-06-30 $-1,134
2021-03-31 $-1,038
2020-12-31 $-889
2020-09-30 $-769
2020-06-30 $-653
2020-03-31 $-532
2019-12-31 $-440
2019-09-30 $-367
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $4.260B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00